By Infinium Global Research Aug, 2020
The glycated hemoglobin is the one form of hemoglobin that
used to measured average plasma glucose concentration. The glycated hemoglobin
testing is a measured amount of glycosylated hemoglobin in the blood. Glycated
hemoglobin test shows the blood glucose levels over the past six to eight weeks
and helps to determine how diabetes is being controlled over time. The rapidly
growing occurrence of diabetes across the globe drives the growth of the
glycated hemoglobin test market. According to the WHO, 422 million adults have
been diagnosed with diabetes globally and it has been steadily increasing in
the low level and middle-level people. Diabetes is one of the leading causes of
death in the world so they need effective and accurate tests to determine
and control diabetes are rising very rapidly. The rising geriatric population
and growing awareness about diabetes are contributing to the growth of the
glycated hemoglobin market. However, high costs associated with glycated
hemoglobin testing devices are hampering the growth of the glycated hemoglobin
testing market. Moreover, technological advancements in monitoring technologies
and devices and the growing geriatric population are projected to create
several opportunities in the glycated hemoglobin test market.
The report on global glycated hemoglobin testing market
covers segments such as type, technique, and end-user. The report provides
regional analysis covering geographies such as North America, Europe,
Asia-Pacific, and Rest of the world In this section, the key trends and market
size for each geography are provided over the period of 2016-2024. The report
provides profiles of the companies in the global Abbott Laboratories Inc.,
Bio-Rad Laboratories, Inc., Danaher Corporation, Roche Holdings AG, Randox
Laboratories Ltd., Siemens AG, Sebia SA, A. Menarini Diagnostics Ltd., and
Trinity Biotech Inc.